REPORT DESCRIPTION
Phenylketonuria Treatment Market – Overview
Phenylketonuria (PKU) is a rare genetic disorder caused due to increased level of phenylalanine in the
blood. The excess amount of phenylalanine can cause intellectual disability and other serious health
problems. The most severe condition of this disorder is termed as classic PKU and symptoms related to it
are seizures, tremors, or trembling and shaking, stunted growth, hyperactivity, skin conditions such as
eczema, and musty odor of their breath, skin, or urine. PKU can be managed by maintaining phenylalanine
free diet. KUVAN (sapropterin dihydrochloride) is a U.S. Food and Drug Administration approved drug
which is majorly used in the treatment of Phenylketonuria.
Frequent research for development of novel drugs for the treatment of phenylketonuria is expected to drive
growth of global phenylketonuria treatment market in the near future. For instance, in 2017, BioMarin
Pharmaceutical Inc.
.